EG VEGF Human

Endocrine Gland Vascular Endothelial Growth Factor Human Recombinant
Cat. No.
BT5323
Source
Escherichia Coli.
Synonyms
PK1, PRK1, Prokineticin 1, EG-VEGF.
Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Purity

Greater than 95.0% as determined by SDS-PAGE.

Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock
Quick Inquiry

Description

EG-VEGF Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 86 amino acids and having a molecular mass of 9.7kDa. The EG-VEGF is purified by proprietary chromatographic techniques. 

Product Specs

Introduction
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) plays a crucial role in the formation and function of blood vessels within endocrine glands. It promotes the growth, movement, and specialized window-like structures in the cells lining these blood vessels. Produced primarily in the steroid-producing glands like ovaries, testes, adrenal glands, and placenta, EG-VEGF production increases in low-oxygen conditions. Its activity often complements that of VEGF, indicating a coordinated effort in blood vessel regulation. Additionally, EG-VEGF can cause contractions in the smooth muscles of the digestive system.
Description
This product consists of a single, non-glycosylated polypeptide chain of EG-VEGF, produced in E. coli bacteria. Containing 86 amino acids, it has a molecular weight of 9.7kDa. The EG-VEGF is purified using specialized chromatographic techniques to ensure its high quality.
Physical Appearance
The product appears as a white powder, sterilized by filtration and freeze-dried.
Formulation
The EG-VEGF protein is freeze-dried from a solution containing a concentration of 1mg/ml in 0.1% Trifluoroacetic Acid (TFA).
Solubility
To reconstitute the freeze-dried Endocrine Gland Vascular Endothelial Growth Factor, it is recommended to dissolve it in sterile 18MΩ-cm H2O to a concentration of at least 100µg/ml. This solution can be further diluted in other aqueous solutions as needed.
Stability
While the lyophilized EG-VEGF Human Recombinant remains stable at room temperature for up to 3 weeks, it is best stored in dry conditions below -18°C. Once reconstituted, store EG-VEGF at 4°C for a maximum of 7 days. For long-term storage, keep it below -18°C. Avoid repeated freezing and thawing cycles.
Purity
The purity of this product exceeds 95.0%, as assessed by SDS-PAGE analysis.
Biological Activity
The biological activity of this product is determined by its ability to stimulate the growth of MIA PaCa-2 cells in a dose-dependent manner. Typically, the effective concentration range is between 1-4 µg/ml.
Synonyms
PK1, PRK1, Prokineticin 1, EG-VEGF.
Source
Escherichia Coli.
Amino Acid Sequence
AVITGACERD VQCGAGTCCA ISLWLRGLRM CTPLGREGEE CHPGSHKVPF FRKRKHHTCP CLPNLLCSRF PDGRYRCSMD LKNINF.

Product Science Overview

Discovery and Expression

EG-VEGF was first identified as a tissue-specific angiogenic factor with its expression pattern restricted to endocrine glands, including the testis, ovary, adrenal gland, and placenta . The highest expression of EG-VEGF is observed in the testis, particularly in Leydig cells . This factor is involved in promoting proliferation, migration, and fenestration of endothelial cells in these tissues .

Function and Mechanism

EG-VEGF functions by binding to its receptors, Prokineticin Receptor 1 (PK-R1) and Prokineticin Receptor 2 (PK-R2), which are expressed in endothelial cells of endocrine glands . The binding of EG-VEGF to these receptors triggers a cascade of signaling events that lead to endothelial cell proliferation and new blood vessel formation . This process is vital for the transport of hormones and nutrients to and from the endocrine glands .

Human Recombinant EG-VEGF

Human recombinant EG-VEGF is produced through genetic engineering techniques, allowing researchers to study its angiogenic properties and explore its potential therapeutic applications . Recombinant EG-VEGF has been used in various studies to understand its role in normal and pathological angiogenesis, particularly in endocrine-related disorders .

Clinical Implications

The expression of EG-VEGF has been linked to several clinical conditions. For instance, its expression in Leydig cell tumors suggests a role in tumor angiogenesis and growth . Additionally, EG-VEGF has been studied for its potential therapeutic applications in treating endocrine disorders and promoting tissue regeneration .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

Related Products

EG VEGF Mouse
Endocrine Gland Vascular Endothelial Growth Factor Mouse Recombinant
Cat. No.
BT5987
Source
Escherichia Coli.
THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.